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INTRODUCTION
Living with ESBLs
b-Lactams remain the most ﬂexible antibiotic
class, owing to their versatility and diversity in
terms of chemical properties, antibacterial spectra
and administration schedules. The major threat
for these compounds is the ever-growing diver-
siﬁcation and proliferation of b-lactamases.
Among more than 350 different b-lactamases
identiﬁed, almost one-third of them are able to
hydrolyse broad-spectrum cephalosporins and
aztreonam, although many of these are minor
variants of a few major types.
Various deﬁnitions of extended-spectrum
b-lactamases (ESBLs) have been in use over the
past 20 years, some based on spectrum and
inhibition, and others on evolutionary history.
No deﬁnition is perfect but, in an attempt to be
both comprehensive and pragmatic, a deﬁnition
was proposed during the ESCMID conference, the
proceedings of which are presented in this issue:
‘an ESBL is any b-lactamase, ordinarily acquired
and not inherent to a species, that can rapidly
hydrolyse, or confer resistance to, oxyimino-
cephalosporins (not carbapenems) or any b-lac-
tamase mutant, within a family, that has an
enhanced ability to do so’ [D. Livermore].
ESBLs are clearly a matter for global concern
but, like other bacterial resistance mechanisms,
they evolve and spread differently in different
settings. While clonal spread of strains of ESBL-
producing Escherichia coli has been reported in
some countries and care settings, in most coun-
tries it is mobile genetic elements encoding the
ESBLs that are spreading among clonally unre-
lated strains. In Europe, CTX-M ESBLs, which
began to disseminate clinically later than the
classical TEM and SHV variants, are now spread-
ing rapidly and are increasingly dominant.
In contrast, ESBL producers in the USA still
mainly have TEM and SHV mutant b-lactamases,
and CTX-M types have only rarely been identi-
ﬁed. In Latin America, or at least in Argentina,
ESBLs are highly prevalent but belong to groups
different from those prevalent in Europe and the
USA. The high prevalence potentially can be
attributed to many factors, e.g., uncontrolled use
of broad-spectrum antibiotics, limited identiﬁca-
tion of ESBL-producing bacteria in microbiology
laboratories due to economic constraints, and the
likelihood of transmission among patients be-
cause of overcrowded hospitals and shortcom-
ings of contact barriers and hand-washing
procedures.
Initially found among hospitalised patients and
in species more common in the intensive care
setting (e.g., Klebsiella pneumoniae and Enterobacter
cloacae), ESBLs are now commonly found in E. coli
isolates from patients in nursing homes and long-
term-care facilities, and even in patients with
community-acquired infections. Although uri-
nary tract infections are the most frequent
primary site for community-acquired infections
caused by ESBL-producing bacteria, 5–15% of
community-acquired infections caused by ESBL-
producing E. coli involve bacteraemia, and this
ﬁgure continues to increase. Thus, protocols for
the empirical treatment of community-acquired
sepsis need to be revised, particularly in areas
where E. coli strains with ESBLs are prevalent.
Antimicrobial susceptibility testing of third-
generation cephalosporins is currently based on
both breakpoints and screening tests to predict
and conﬁrm the presence of ESBLs. The growing
number of species that are likely to produce
ESBLs and the increasing number of different
ESBLs tend to broaden the range of MIC values
and degrees of synergy likely to be seen for ESBL
producers, complicating ESBL detection methods.
This situation mandates reassessment of suscep-
tibility breakpoints of third-generation cephalo-
sporins for Enterobacteriaceae on both sides of the
Atlantic. Low cephalosporin breakpoints alone (as
adopted by EUCAST) will facilitate detection of
likely ESBL producers, but will not obviate the
need for speciﬁc ESBL identiﬁcation, since this is
of epidemiological importance. Effective interpre-
tive rules for in-vitro tests are urgently needed,
since some ESBL producers appear to be suscep-
tible to cephalosporins in vitro but have been
associated with treatment failure and increased
mortality. The CLSI recommends reporting ESBL-
producing strains of E. coli and Klebsiella spp. as
resistant to all penicillin, cephalosporin and
monobactam antimicrobials (it provides no guid-
ance concerning ESBLs in other species), but
accepts results for b-lactam–b-lactamase inhibitor
combinations as found. In fact, several clinical
experiences with b-lactam–b-lactamase inhibitor
combinations have been variable, and these com-
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pounds are less active against organisms produc-
ing multiple ESBLs. Moreover, frank in-vitro
resistance to them is increasing among ESBL
producers.
Most notably in the case of clavulanate, whose
good activity is critical in ESBL detection tests, the
therapeutic potential is uncertain, partly because
of difﬁcult-to-protect penicillins in the marketed
combinations and partly because of its potential
antagonistic activities against cephalosporins
through induction of AmpC synthesis.
Since the ESBL-producing organisms fre-
quently also carry genes encoding resistance to
other antibiotic classes, including quinolones,
aminoglycosides, tetracyclines and antifolates,
the therapeutic options are seriously reduced.
The parenteral carbapenems are widely consid-
ered to be the most effective treatment for serious
infections caused by ESBL producers. Imipenem
and meropenem, which are active against both
Enterobacteriaceae and non-fermentative Gram-
negative bacilli, are licensed in Europe for many
indications, covering almost all severe and noso-
comial infections. Ertapenem, with limited activ-
ity against non-fermentative Gram-negative
bacilli, has been licensed in the EU since 2002
for the treatment of intra-abdominal infections,
community-acquired pneumonia, acute pelvic
infections and soft-tissue infections associated
with diabetic foot. Panipenem, with a spectrum
similar to ertapenem, and biapenem, with in-vitro
activity comparable to imipenem and merope-
nem, are available in Japan and South Korea, and
several other carbapenems are under develop-
ment, e.g., doripenem. Carbapenems with oral
activity for community use, e.g., tebipenem, have
demonstrated broad-spectrum antibacterial activ-
ity, including activity against ESBL producers, but
their development looks uncertain.
While the spread of ESBLs is a driver for
increasing use of carbapenems, the growing
diffusion of carbapenem-hydrolysing enzymes
among Enterobacteriaceae in some European
countries mandates strict control over their use
and careful monitoring of susceptibility trends.
In conclusion, laboratory ﬁndings and clinical
experiences both show that the ESBL problem is
rapidly evolving and increasing in severity, espe-
cially in Europe. New ESBLs, particularly the
CTX-M types, are spreading. Producers are no
longer conﬁned to intensive care units, but are
being isolated from community patients. E. coli,
rather than Klebsiella spp., is becoming the main
host. The challenge posed, which is a deﬁnite
threat to the future of antimicrobial chemother-
apy, must be seriously addressed by the labora-
tory, by the clinicians treating infected patients,
by public health and infection control profession-
als, and by the pharmaceutical industry.
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